TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Fascial Defect Closure for Minimally Invasive Parastomal Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years or older~* End or loop-end stoma with a parastomal defect - candidate for minimally invasive Sugarbaker repair at the discretion of the staff surgeon.~* Anticipated parastomal fascial defect should not exceed 7cm in any direction~* Patient able to tolerate a minimally invasive repair, the surgeon can achieve minimally invasive access and complete a minimally invasive adhesiolysis.~* Bowel able to be lateralized at least 4cm beyond the edge of the parastomal fascial defect~Exclusion Criteria:~* Loop stoma~* Parastomal fascial defect \>7cm~* Concomitant ventral defect or complexity of the repair warrants open repair at the discretion of the staff surgeon~* Minimally invasive Sugarbaker repair with intraperitoneal mesh cannot be achieved.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fascial closure (Type: ACTIVE_COMPARATOR): This arm will have the parastomal fascial defect closed with a running barbed suture prior to mesh placement.
- No fascial closure (Type: NO_INTERVENTION): This arm will undergo mesh placement +/- fixation without the fascial defect being closed prior.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completed a clinical trial evaluating casimersen or golodirsen, per protocol.~* Is between 7 and 23 years of age, inclusive, at enrollment.~Other inclusion/exclusion criteria apply.

- Gender: MALE
- Minimum Age: 7 Years
- Maximum Age: 23 Years
- Healthy Volunteers: f

Study Arms:
- Casimersen (Type: EXPERIMENTAL): Patients amenable to exon 45 skipping who have completed a clinical trial evaluating casimersen will receive open-label casimersen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
- Golodirsen (Type: EXPERIMENTAL): Patients amenable to exon 53 skipping who have completed a clinical trial evaluating golodirsen will receive open-label golodirsen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose.~2. Have plaque type psoriasis covering at least 15% of total BSA at Day 1 (at the time of the first study dose).~3. Have a PASI score of 12 or greater at Day 1 (at the time of the first study dose).~4. Be a candidate for phototherapy or systemic treatment of psoriasis (either naïve or history of previous treatment).~Exclusion Criteria:~1. Currently have non plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis.~2. 3. Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium.~3. Have received any of the following treatment regimens specified in the timeframes outlined below:~Within 9 months of first dose of study drug:~• Ustekinumab (Stelara).~Within 12 weeks of first dose of study drug:~• Any experimental therapy for psoriasis or rheumatoid arthritis.~Within 4 8 weeks of first dose of study drug:~* Biologic therapies for psoriasis have discontinuation periods determined from approximately 5x half life of the respective biologic:~* 4 weeks: etanercept (Enbrel).~* 8 weeks: infliximab (Remicade), adalimumab (Humira).~Within 4 weeks of first dose of study drug:~* Systemic treatments other than biologics that could affect psoriasis (eg, oral or injectable corticosteroids, retinoids, methotrexate, cyclosporine, fumaric acid derivatives, sulfasalazine, hydroxycarbamide (hydroxyurea), azathioprine).~* Phototherapy and psoralen plus ultraviolet A therapy (PUVA).~* Other - intramuscular gold, immunization with any live virus vaccination (eg, FluMist), herbal medications.~Within 2 weeks of first dose of study drug:~* Topical treatments that could affect psoriasis (eg, corticosteroids, tars, keratolytics, anthralin, vitamin D analogs, and retinoids).~* Phototherapy with ultraviolet B (UVB) (narrowband or broadband).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 200mg of PF-04965842 twice daily
- Cohort 2 (Type: EXPERIMENTAL): 400mg of PF-04965842 once daily
- Cohort 3 (Type: EXPERIMENTAL): 200mg of PF-04965842 once daily
- Cohort 4 (Type: PLACEBO_COMPARATOR): Placebo comparator daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Palliation of Dyspnea With Mouth Piece Ventilation in AECOPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* a previous diagnosis of COPD~* hospitalized due to acute exacerbation of COPD~* at least moderate dyspnea (NRS = Numeric Rating Scale ≥ 4)~* no acute hypoventilation (pH ≥ 7.35 and PCO2 ≤ 6.0 kPa)~* able to understand the study and to give informed consent~Exclusion Criteria:~* unable to participate and use MPV due to e.g. delirium or lack of co-operation~* acute hypoventilation (pH \< 7.35 or PCO2 \> 6.0 kPa)~* acute need for ventilatory support~* the cause of the dyspnea can be successfully treated~* unable to give informed consent~* a previous chronic hypoxemic or hypercapnic respiratory insufficiency that has been treated on a long-term basis also at home

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MPV-arm (Type: EXPERIMENTAL): Subjects use mouth piece ventilation (MPV) according to their will for 24 hours to alleviate dyspnea.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: POCUS-PEAC to Reduce Femoral Arterial Blood Flow

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age 18 to 40 years old~Exclusion Criteria:~* \<18 years old, \>40 years old, BMI \<18 or \>25, History of abdominal surgery, history of vascular surgery, known aortic disease, known peripheral vascular disease, coronary disease, smoking, history of smoking, diabetes, dislipidemia, arterial hypertension, abdominal or inguinal hernia, eating in the last 4 hours before intervention, abdominal pain on the day of intervention, abdominal bloating on the day of intervention, pregnancy, impossibility to visualize the aorta with the ultrasound

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Electroconvulsive Treatment Followed by Cognitive Control Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged between 18 and 70 years old~* current major depressive episode with treatment resistance~* eligibility and consent for ECT treatment~* ability to provide consent to study~Exclusion Criteria:~* neurodegenerative disorder or Montreal Cognitive Assessment (MOCA) \< 18~* catatonia~* schizophrenia~* alcohol use disorder in previous year~* prior ECT treatment~* insufficient computer knowledge or analphabetism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive control training (Type: EXPERIMENTAL): Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
- Active Control (Type: ACTIVE_COMPARATOR): Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Positive diagnosis of first episode of NAION in the study eye with symptom onset within 14 days prior to planned study drug administration/sham procedure~* Best corrected visual acuity score in the study eye is better than or equal to 15 letter score, measured using the ETDRS visual acuity protocol at Day 1 prior to study drug administration/sham procedure.~* Clear ocular media and able to undergo adequate pupil dilation to allow a good fundus examination~Key Exclusion Criteria:~* Present use or history of any treatment for the current episode of NAION, including systemic steroids, brimonidine, or traditional Chinese herbal medicine~* Prior episode of NAION in the study eye only~* Present use of drugs known to cause optic nerve or retinal toxicity at Day 1/Randomization, such as: chloroquine or hydroxychloroquine, ethambutol, Vigabatrin. Subjects who need to be prescribed any of these drugs during the course of the study will be discontinued from the trial.~* Any medical condition, concomitant therapy, or previous incisional or laser surgery that, in the opinion of the Investigator, would preclude IVT injection in the study eye only~* Clinical evidence of temporal arteritis

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- single dose or multiple dose (Type: ACTIVE_COMPARATOR): QPI-1007 Injection - 1.5 mg
- single or multiple dose (Type: ACTIVE_COMPARATOR): QPI-1007 Injection - 3.0 mg
- Sham (Type: SHAM_COMPARATOR): Sham injection procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of Systane® Balance in Dry Eye Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sign informed consent and willing and able to attend all study visits;~* Dry eye in both eyes diagnosed by an ophthalmologist;~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Women of childbearing potential who are pregnant or breastfeeding;~* Any medical condition (systemic or ophthalmic) that may preclude the safe administration of test article or safe participation in the study;~* Ocular surgery or ocular trauma requiring medical or pharmacological treatment within 1 year of Screening;~* Use of topical ocular prescription or non-prescription medications, RESTASIS or topical ocular steroids within 14 days of Screening;~* Use of any artificial tears/gels/lubricants/rewetting drops within 4 hours of Screening;~* Contact lens wear within 1 week of Screening and/or unwillingness to discontinue contact lens wear for the duration of the study;~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Systane Balance (Type: EXPERIMENTAL): Propylene Glycol 0.6% eye drops, 1 drop QID (with the last dose of each day at bedtime) in each eye for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients at the age of 18 to 75 years old~2. Histologically or cytologically diagnosed NSCLC cases~3. Thrombocytopenia occurred in the selected chemotherapy cycle confirmed by double test results with platelet count lower than 75×109/L~4. Fit for chemotherapy (WBC ≥ 4.0×109/L；neutrophil count\> 1.5×109/L；PLT ≥ 80×109/L；ALT ≤ 3 times the upper limit of normal range；AST ≤ 3 times the upper limit of normal range；TBil ≤ twice the upper limit of normal range；ECOG PS ≤ 2；without severe cardiopulmonary defects)~5. Expected lifespan over 12 weeks~6. With understanding ability and voluntarily sign informed consent form~7. Be able to comply with the study and follow-up process~Exclusion Criteria:~1. With any unstable systemic diseases including active infection, uncontrolled hypertension, liver diseases, renal diseases or metabolic diseases~2. With uncontrolled brain metastasis symptoms (patients whose brain metastasis controlled over 4 weeks without hormone therapy can still be enrolled)~3. With heart cerebrovascular diseases, congestive heart failure with NYHA above II degree, with unstable angina pectoris, with acute myocardial infarction or cerebral infarction within 6 months~4. Breast-feeding or pregnant women~5. Platelet count over 300×109/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): rhTPO(recombinant human thrombopoietin) is given on the second, 4th and 9th day of the chemotherapy cycle in a dosage of 15000U once subcutaneously.
- Control group (Type: ACTIVE_COMPARATOR): 15000U of rhTPO(recombinant human thrombopoietin) is given subcutaneously 6 to 24 hours within the end of chemotherapy cycle, that is, the 8th day for 3 consecutive days (d9 to d11)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants are eligible to be included in the study only if all the following criteria apply:~* Participants who will receive artificial frozen-thawed embryo transfer (FET) cycle study interventions~* Participants who have no more than two Day 5 embryos are planned to be transferred (follow the clinical practice of the study site)~* Participants have received estradiol valerate for no more than 20 days~* Participants have a transitional-endometrium of greater than or equal to 8 millimeter~* Participants have normal uterine cavity~* Participants can give signed informed consent~* Participants are willing to follow the study protocol and able to complete the study~Exclusion Criteria:~* Participants are willing to follow the study protocol and able to complete the study~* Participants with greater than or equal to three previously failed cycles of ET~* Participants with diseases that cannot tolerate pregnancy~* Hydrosalpinx~* Severe endometriosis (Endometriosis American Society for Reproductive Medicine (ASRM) criteria from 1996)~* Known hypersensitivity to progesterone, the excipients of Crinone and Duphaston Vaginal bleeding of unknown origin~* History of recurrent miscarriages~* Vaginitis~* Thromboembolic diseases (thrombophlebitis, thromboembolic disorder, or cerebral apoplexy) or participants with a history of these conditions~* Known or suspected progestogen-dependent neoplasm~* Participation in another clinical trial within the past 30 days~* Contraindications of both Crinone and Duphaston

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Crinone (Type: EXPERIMENTAL): Participants received Crinone 8% (90 milligrams \[mg\] an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.
- Crinone plus Duphaston (Type: EXPERIMENTAL): Participants received Crinone 8% (90 mg an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning followed by 10 mg of Duphaston tablet orally twice a day from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Bleeding Prevention in Massive Bone Tumour Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years and older~* Musculoskeletal tumor (primary or metastatic, benign or malignant) located in extremities, shoulder girdle or pelvis.~* Massive or bloc tumour resection.~* Patient's consent to participate~Exclusion Criteria:~* Known allergy to ATX~* Allergy or known hypersensitivity to bovine proteins (aprotinin)~* Liposarcomas low grade~* History of thromboembolic disease or prothrombotic conditions:~  * cerebral vascular accident~ * ischemic heart disease~ * deep and / or superficial vein thrombosis~ * pulmonary embolism~ * peripheral arterial vasculopathy~ * thrombogenic arrhythmias (eg: ACxFA)~ * patients with cardiovascular stents~ * prothrombotic alterations in coagulation~* Treatment with contraceptive drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tranexamic acid (Type: EXPERIMENTAL): Tranexamic acid, 1g intra-articular before closing the surgery wound
- Fibrin glue (Type: EXPERIMENTAL): One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery
- Usual hemostasia (Type: ACTIVE_COMPARATOR): Electrocauterization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patients Response to Early Switch To Oral:Osteomyelitis Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Only adult patients will be invited to participate in this trial (age ≥ 18 years). A patient will be considered a candidate to participate in this trial if the following two inclusion criteria are present:~  1. Isolation of an organism from bone culture that is susceptible to intravenous and oral antibiotics.~ 2. Plus at least one of the following:~     * Evidence of local inflammatory response, manifested as local pain, edema, erythema, warmth, or drainage.~    * Evidence of systemic inflammatory response, manifested as fever, elevated C---reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), or white blood cell count.~* \*Osteomyelitis---compatible findings on plain radiograph, computed tomography, bone scan, magnetic resonance imaging, or positron emission tomography.~  * Pathology report indicative of osteomyelitis.~Exclusion Criteria:~* A patient will not be considered as a candidate to participate in this study if the study team expects the subject to be non---compliant with the study follow---up clinic visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous antibiotics (Type: ACTIVE_COMPARATOR): Intravenous antibiotics for the full duration of therapy
- oral antibiotics (Type: ACTIVE_COMPARATOR): intravenous antibiotic therapy plus early switch to oral antibiotic therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues